Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
Titel:
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
Auteur:
Zhang, J. Liu, R. Wang, S. Feng, Z. Yang, H. Gao, S. Li, X. Yao, X. Chen, J. Gong, Z. Li, Y. Li, X. Wang, S. Hu, C. Liu, J. Zhang, M. Yuan, F. Shi, B. Lou, H. Zhao, P. Qiu, F. Guo, H. Hu, B. Xu, D. Huang, H. Zhang, X. Feng, M. Wang, X. Li, G. Liu, D. Chen, X. Wang, P.